16:39 , Mar 27, 2018 |  BC Extra  |  Preclinical News

Baylor team suggests new way to attack triple-negative breast cancer

In a paper published in Nature Medicine, researchers from Baylor College of Medicine and colleagues suggest that specifically targeting multiple RTKs regulated by protein tyrosine phosphatase non-receptor type 12 (PTPN12), a tumor suppressor frequently inactivated...
20:50 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) In vitro, cell culture and mouse studies identified two USP10 inhibitors that could help treat AML harboring internal tandem duplication (ITD) mutations in FLT3. Screening of deubiquitinating enzyme (DUB) inhibitors in...
21:19 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Crenolanib regulatory update

Arog said FDA granted Fast Track designation to crenolanib besylate to treat unresectable or metastatic gastrointestinal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) D824V mutation. Crenolanib besylate is in Phase III testing...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Aflibercept/rinucumab: Phase II data

Top-line data from the double-blind, U.S. and Japanese Phase II CAPELLA trial in about 500 patients with wet AMD showed that intravitreal injections of 2/1 mg and 2/3 mg REGN2176-3 aflibercept/rinucumab every 4 weeks each...
07:00 , Sep 30, 2016 |  BC Extra  |  Clinical News

Regeneron combo fails to top Eylea alone in AMD study

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) said intravitreal injections of REGN2176-3 missed the primary endpoint in the ongoing Phase II CAPELLA study to treat wet age-related macular degeneration. The therapy, which combines the company's ophthalmic drug...
01:35 , May 3, 2016 |  BC Extra  |  Financial News

Ophthalmic play Graybug raises $44.5M

Graybug Vision Inc. (Redwood City, Calif.) raised $44.5 million in a series B round led by new investor Deerfield. New investors OrbiMed Advisors and Clarus Ventures also participated, along with existing investor Hatteras Venture Partners....
00:45 , Mar 25, 2016 |  BC Extra  |  Company News

Regeneron, Bayer strike another Eylea combo deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) granted Bayer AG (Xetra:BAYN) exclusive ex-U.S. rights to a combination including Regeneron's nesvacumab ( REGN910) and its ophthalmic drug Eylea aflibercept ophthalmic solution. The combination, formulated as a single intravitreal injection,...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Sarcoma EPH receptor B4 (EPHB4); platelet derived growth factor receptor B (PDGFRB; PDGFR1; CD140B) Patient sample and...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Platelet derived growth factor receptor B (PDGFRB; PDGFR1; CD140B) Studies in mice and human samples...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Regeneron, Bayer deal

Regeneron and Bayer partnered to develop Regeneron's antibody against platelet derived growth factor receptor B ( PDGFRB; PDGFR1; CD140B) as a combination therapy with the partners' Eylea aflibercept to treat wet...